Stock listing

NASDAQ:CYCN Cyclerion Therapeutics, Inc. Stock

Home listing (NASDAQ) of Cyclerion Therapeutics, Inc.

Follow Cyclerion Therapeutics, Inc. into a list and get an email when it puts out news.

Cyclerion Therapeutics, Inc. logo
Ticker
NASDAQ:CYCN
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Cyclerion Therapeutics, Inc. news

Cyclerion Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
3 in the last 12 months · 47 in all · newest Apr 1, 2026 · oldest 2019
Decks
22 decks · latest July 2026

Where Cyclerion Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:CYCN · Home listing · This pageNASDAQUnited StatesUSD
BOATS:CYCNBOATSUnited StatesUSD

Valuation

Statements: Year to Dec 31, 2025 · balance Sep 30, 2026

Enterprise value
No market cap
P/E
No market cap
EV/sales
No market cap
EV/EBITDA
No market cap
Price/book
No market cap
Gross margin
100.0%
Operating margin
−239.8%
Net margin
−170.1%
Debt to equity
0.0×
Beta vs S&P 500
0.49

Forecasts

1 strong buy · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.

Price target
56.00 USD · Analysts' mean
EPS, year to Dec 2026
-8.40 · 1 analyst

Team and board

Officers

OfficerRole
Jonathan ViolinChief Executive Officer
Mark VignolaChief Financial Officer
Eva StroynowskiVP, Investor Relations
Angela SheVP, R&D Strategy and Operations
Joshua ParkVP, Protein Sciences
Kyle BreidenstineSVP, Finance
Maribel ReyesVP, Clinical Pharmacology and Translational Science
Michael OldhamVP, Clinical Development
Robin WojcieszekSVP, Regulatory, Drug Safety and Medical Writing
Vanessa TeachoutVP, Head of Clinical Operations
Gan WeiChief Technology Officer
Matthew LeoniChief Medical Officer

Board

DirectorRole
Tomas KiselakChairman
Andrew GottesdienerDirector
Heidi HensonDirector
Jonathan ViolinChief Executive Officer
Michelle PerniceDirector
Nimish ShahDirector

Events

QuarterResultsShare move
Q2 2026Aug 4, 2026+1.7%
Q4 2025Mar 31, 2026 · Before open+7.3%
Q3 2025Nov 12, 2025−10.6%
Q2 2025Aug 5, 2025−14.2%
Q1 2025May 5, 2025 · After close+1.3%
Q4 2024Mar 3, 2025 · After close+9.6%
Q3 2024Nov 11, 2024 · After close−23.4%
Q2 2024Aug 7, 2024 · Before open−1.1%
Q1 2024May 7, 2024 · After close+1.0%
Q4 2023Mar 5, 2024 · After close−3.4%
All 20 quarters
QuarterResultsShare move
Q3 2023Nov 13, 2023 · After close−9.1%
Q2 2023Jul 28, 2023 · After close+14.2%
Q1 2023May 12, 2023 · Before open−25.1%
Q4 2022Mar 22, 2023 · After close−11.6%
Q3 2022Nov 3, 2022 · After close−20.5%
Q2 2022Aug 9, 2022 · After close+1.0%
Q1 2022May 4, 2022 · After close−5.3%
Q4 2021Feb 24, 2022 · After close−3.5%
Quarter to Sep 30, 2021Nov 9, 2021 · After close−5.4%
Quarter to Jun 30, 2021Jul 29, 2021 · After close−0.7%

Open Events

Decks

DeckKindSlidesDate
Korsana Biosciences — Merger or Acquisition (July 2026)Merger or acquisition32 slidesJuly 2026
Merger or Acquisition (April 2026)Merger or acquisition52 slidesApr 1, 2026
Merger or Acquisition (April 2026)Merger or acquisition56 slidesApr 1, 2026
Korsana Biosciences — Merger or Acquisition (April 2026)Merger or acquisition31 slidesApril 2026
Investor Presentation (February 2026)Investor deck22 slidesFeb 17, 2026
Korsana Biosciences — Investor Presentation (February 2026)Investor deck28 slidesFebruary 2026
Investor Presentation (January 2026)Investor deck28 slidesJan 6, 2026
Investor Presentation (January 2026)Investor deck23 slidesJanuary 2026
Investor Presentation (January 2026)Investor deck22 slidesJanuary 2026
Corporate Update (September 2025)Corporate update15 slidesSep 23, 2025
All 22 decks
DeckKindSlidesDate
Technical Presentation (July 2022)Technical30 slidesJul 28, 2022
Investor Presentation (June 2022)Investor deck63 slidesJun 10, 2022
Investor Presentation (September 2021)Investor deck59 slidesSep 30, 2021
Investor Presentation (April 2021)Investor deck59 slidesApr 27, 2021
Corporate Update (January 2021)Corporate update37 slidesJan 13, 2021
Corporate Update (October 2020)Corporate update24 slidesOct 14, 2020
Investor Presentation (July 2020)Investor deck37 slidesJul 9, 2020
Corporate Update (July 2020)Corporate update35 slidesJul 9, 2020
UMDF Power Surge 2020Conference7 slidesJun 26, 2020
Corporate Update (April 2020)Corporate update35 slidesApr 14, 2020
J.P. Morgan Healthcare Conference 2020Conference16 slidesJan 13, 2020
Corporate Update (October 2019)Corporate update17 slidesOct 30, 2019

Open Decks

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue2.07M2.00M0297.0K3.32M2.30M4.51M000
Cost of revenue1.31M5.58M472.0K56.4M95.1M1.53M1.75M2.17M
Gross profit2.07M2.00M-1.31M-5.28M3.32M-54.1M-90.6M-1.53M-1.75M-2.17M
Research and development959.0K286.0K1.51M5.98M37.6M56.4M95.1M87.7M78.8M50.9M
Selling, general and administrative6.09M5.34M8.13M12.9M20.6M28.8M34.4M27.5M15.1M12.7M
Operating income-4.97M-3.63M-13.0M-18.5M-55.2M-81.3M-125.0M-115.3M-93.9M-63.6M
Depreciation and amortization65.0K65.0K472.0K2.30M2.70M1.53M1.75M2.17M
EBITDA-12.9M-18.5M-54.7M-79.0M-122.3M-113.7M-92.2M-61.4M
Interest expense294.0K16.0K588.0K0000
Income before tax-3.53M-3.06M-12.6M-18.2M-51.6M-77.8M-123.0M-115.3M-93.9M-63.6M
Income tax8.42M-294.0K16.0K-5.13M-2.03M1.37M00
Net income-3.53M-3.06M-5.26M-44.1M-51.6M-77.8M-123.0M-115.3M-93.9M-63.6M
Earnings per share, basic-7.66-8.50-15.76-141.99-184.72-358.26-628.97-590.94-481.58-324.71

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents3.24M3.23M7.57M13.4M54.0M54.4M97.6M000
Short-term investments000
Receivables1.00M556.0K096.0K100.0K127.0K1.47M
Inventory805.0K928.0K816.0K1.97M000
Current assets4.63M4.22M8.02M14.8M55.5M58.5M101.2M879.0K1.26M275.0K
Property, plant and equipment1.22M1.47M6.87M79.8M6.50M4.13M3.60M
Goodwill000
Total assets9.98M9.57M13.4M18.1M59.3M115.4M186.5M7.40M5.47M3.88M
Accounts payable508.0K390.0K1.20M2.97M1.83M1.15M3.31M2.78M1.80M1.41M
Current liabilities900.0K725.0K2.09M7.63M11.1M17.0M18.2M17.8M14.0M10.6M
Long-term debt000
Total debt45.7M73.9M
Total liabilities900.0K725.0K2.09M7.63M11.1M55.9M88.7M17.8M14.0M10.6M
Shareholders' equity9.09M8.85M11.3M10.5M48.2M59.5M97.7M-10.4M-8.57M-6.76M
Shares outstanding460.7K359.7K334.0K310.4K279.6K217.2K195.6K195.0K195.0K195.7K

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-3.31M-4.33M-21.2M-40.6M-36.5M-72.5M-102.2M-97.5M-81.2M-49.9M
Capital spending0000-7.00K-1.52M-6.89M-3.44M-1.40M-1.45M
Free cash flow-3.31M-4.33M-21.2M-40.6M-36.5M-74.0M-109.1M-100.9M-82.6M-51.3M
Cash from investing10.4M1.46M18.0K-6.71M-3.44M-1.40M-1.45M
Cash from financing3.32M05.02M29.0K30.8M28.1M211.6M100.9M82.6M51.3M
Dividends paid000
Share buybacks-130.0K024.6M165.1M000
Change in cash8.00K-4.34M-5.81M-40.6M-4.27M-44.4M102.6M102.6M102.6M102.6M

Open Financials

Cap table

Built by 6ix from Cyclerion Therapeutics, Inc.’s releases

Common shares
668,764
Fully diluted
668,764

Fully diluted

LineShares
Common shares668,764

Share count over time

CountShares
Nov 22, 2026668,764
Aug 26, 2026

Open Cap table

Shareholders

Funds

HolderSharesOf the companyValueAs of
Fidelity Growth Company Fund218K32.6%US$688KMay 31, 2026
Fidelity Growth Company K6 Fund60,4089.0%US$190KMay 31, 2026
Fidelity Series Growth Company Fund57,3008.6%US$180KMay 31, 2026
Vanguard Extended Market Index Fund30,9154.6%US$105KJun 30, 2026
Fidelity Extended Market Index Fund24,7303.7%US$77,900May 31, 2026
Fidelity Nasdaq Composite Index ETF21,2003.2%US$66,780May 31, 2026
Fidelity Small Cap Growth Fund9,9001.5%US$34,056Jul 31, 2026
Fidelity Small Cap Growth K6 Fund4,9820.74%US$17,138Jul 31, 2026
Fidelity Series Total Market Index Fund3,3670.50%US$10,606May 31, 2026
Dimensional US Sustainability Core 1 ETF3,3180.50%US$11,414Jul 31, 2026
All 16 holders
HolderSharesOf the companyValueAs of
Select Health Care Portfolio3,0000.45%US$9,450May 31, 2026
Fidelity Total Market Index Fund2,2600.34%US$7,119May 31, 2026
Dimensional U.S. Core Equity 2 ETF2,1890.33%US$7,530Jul 31, 2026
VIP Health Care Portfolio1,7000.25%US$5,763Jun 30, 2026
Fidelity Advisor Health Care Fund1,5000.22%US$5,160Jul 31, 2026
Dimensional US Core Equity 1 ETF7480.11%US$2,573Jul 31, 2026

Big stakes

StakeStakeSharesDateFiling
Peter M. Hecht19.40%910KJul 16, 2026Schedule 13D
FMR LLC15.00%650KApr 30, 2026Schedule 13G
Balyasny Asset Management L.P.7.33%318KJun 30, 2026Schedule 13G
ADAR1 Capital Management, LLC7.00%299KJun 30, 2026Schedule 13G
J. Wood Capital Advisors LLC5.40%182KMar 25, 2025Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Terrance McGuire
Other companies: Tectonic Therapeutic, Inc. (Director · Since at least Jun 20, 2024); Invivyd, Inc. (Director · Since at least Aug 5, 2021); Seer, Inc. (Director · Since at least Dec 3, 2020); Alector, Inc. (Director · Feb 6, 2019 – Sep 11, 2023 · Past); X4 Pharmaceuticals, Inc. (Director · Nov 15, 2017 – Jun 5, 2018 · Past); Pulmatrix, Inc. (Director · Jun 15, 2015 – May 16, 2019 · Past); Trevena, Inc. (Director · Jan 30, 2014 – May 14, 2014 · Past); Acceleron Pharma Inc (Director · Sep 18, 2013 – Mar 2, 2017 · Past); Ironwood Pharmaceuticals, Inc. (Director · Jun 3, 2013 – Apr 1, 2019 · Past)
Director · Apr 1, 2019 – Nov 30, 2023 · Past
Amy Schulman
Other companies: Elevance Health, Inc. (Director · Since at least Dec 10, 2025); Fractyl Health, Inc. (Director · Since at least Feb 1, 2024); Alnylam Pharmaceuticals, Inc. (Chair of the Board · Since at least Jun 20, 2018); Hudson Executive Investment Corp II (Director · Jan 25, 2021 – Apr 13, 2021 · Past); Ironwood Pharmaceuticals, Inc. (Director · May 31, 2018 – Apr 1, 2019 · Past); Blue Buffalo Pet Products Inc (Director · Apr 24, 2018 – Apr 24, 2018 · Past); X4 Pharmaceuticals, Inc. (Director · Nov 15, 2017 – Jun 5, 2018 · Past)
Director · Apr 1, 2019 – Jun 16, 2020 · Past
Errol B Desouza
Other companies: Alector, Inc. (Director · Since at least Mar 19, 2024); Royalty Pharma plc (Director · Jun 7, 2024 – May 13, 2025 · Past)
Director · Nov 30, 2023 – Nov 30, 2023 · Past
George H Conrades
Other companies: Oracle Corporation (Director · Since at least May 31, 2018); Akamai Technologies, Inc. (Director · Dec 31, 2017 – May 20, 2018 · Past)
Director · Apr 1, 2019 – Jun 14, 2022 · Past
Andreas Busch
Other companies: Absci Corporation (Chief Innovation Officer · Since at least Mar 17, 2022)
Chief Scientific Officer · Apr 29, 2019 – Jan 20, 2022 · Past
Cheryl Gault
Other companies: Rapport Therapeutics, Inc. (Chief Operating Officer · Since at least Jun 6, 2024)
Chief Operating Officer · Jan 1, 2021 – Jan 20, 2022 · Past
Mark G Currie
Other companies: Ironwood Pharmaceuticals, Inc. (Director · Since at least Jan 4, 2016)
President and CSO · Apr 1, 2019 – Dec 28, 2020 · Past
Michael Mendelsohn
Other companies: Foghorn Therapeutics Inc. (Founder, Board Director, & Chief Strategy Officer, Cardurion Pharmaceuticals · Since at least Oct 22, 2020)
Director · Apr 1, 2019 – Jun 14, 2022 · Past
Rhonda M Chicko
Other companies: Scholar Rock Holding Corporation (Chief Financial Officer · May 23, 2018 – Jan 31, 2019 · Past)
Chief Financial Officer · Since at least Mar 4, 2024
Stephanie Lovell
Other companies: TransMedics Group, Inc. (Director · Since at least Mar 22, 2021)
Director · Apr 1, 2019 – Jun 14, 2022 · Past
All 29 people
PersonSeat
Andrew GottesdienerDirector · Since at least Apr 1, 2026
Angela SheVP, R&D Strategy and Operations · Since at least Nov 4, 2026
Eva StroynowskiVP, Investor Relations · Since at least Nov 4, 2026
Gan WeiChief Technology Officer · Since at least Nov 4, 2026
Heidi HensonDirector · Since at least Nov 5, 2026
Jonathan ViolinChief Executive Officer · Since at least Apr 1, 2026
Joshua ParkVP, Protein Sciences · Since at least Nov 4, 2026
Kyle BreidenstineSVP, Finance · Since at least Nov 4, 2026
Maribel ReyesVP, Clinical Pharmacology and Translational Science · Since at least Nov 4, 2026
Mark VignolaChief Financial Officer · Since at least Nov 4, 2026
Matthew LeoniChief Medical Officer · Since at least Nov 4, 2026
Michael OldhamVP, Clinical Development · Since at least Nov 4, 2026
Michelle PerniceDirector · Since at least Apr 1, 2026
Nimish ShahDirector · Since at least Apr 1, 2026
Peter M HechtDirector · Since at least Jul 16, 2026
Regina Margaret GraulSee Remarks, Director · Since at least Aug 14, 2026
Robin WojcieszekSVP, Regulatory, Drug Safety and Medical Writing · Since at least Nov 4, 2026
Tomas KiselakChairman · Since at least Apr 1, 2026
Vanessa TeachoutVP, Head of Clinical Operations · Since at least Nov 4, 2026

Open People

Log in to ask 6ix AI your own questions about Cyclerion Therapeutics, Inc.